Trials / Completed
CompletedNCT01813539
A Study of ARGX-110 in Participants With Advanced Malignancies
A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- OncoVerity, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the optimal dose of ARGX-110 in participants with advanced malignancies and to assess efficacy of ARGX-110 (exploratory efficacy cohort 5 only).
Detailed description
Phase I study conducted in participants whose tumors express the target of interest. Pharmacokinetics (PK), pharmacodynamics (PD), biomarkers will be determined to support dose selection. Phase II study conducted in Cutaneous T-cell lymphoma (CTCL) participants who are CD70 positive. PK, PD, biomarkers and immunohistochemistry (IHC) will be determined to assess efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARGX-110 | ARGX-110 will be administered as an IV infusion. |
Timeline
- Start date
- 2013-02-27
- Primary completion
- 2020-07-10
- Completion
- 2020-07-10
- First posted
- 2013-03-19
- Last updated
- 2023-08-09
Locations
8 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT01813539. Inclusion in this directory is not an endorsement.